Case Report

Jejunal Perforation: A Rare Presentation of Burkitt's Lymphoma—Successful Management

Samir Ranjan Nayak,¹ Ganni Bhaskara Rao,¹
Subramanya Sarma Yerraguntla,² and Sisir Bodepudi¹

¹ Department of Surgery, GSL Medical College & General Hospital, NH-5, Lakshmipuram, Rajahmundry 533294, India

² Department of Medical Oncology, GSL Medical College & General Hospital, Rajahmundry 533294, India

Correspondence should be addressed to Samir Ranjan Nayak; drsaminrayak@gmail.com

Received 26 February 2014; Revised 13 May 2014; Accepted 22 May 2014; Published 4 June 2014

Academic Editor: Junya Kuroda

Copyright © 2014 Samir Ranjan Nayak et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Malignant tumors of the small bowel presenting as acute abdomen are a rare occurrence. Burkitt's lymphoma presenting as a surgical emergency needing emergency laparotomy is an uncommon presentation of this tumor. We present an interesting case of jejunal perforation as a first manifestation of Burkitt's lymphoma which was successfully managed with surgical resection, high dose chemotherapy, and good supportive care.

1. Case Report

1.1. Initial Presentation. 17-year student presented to the emergency ward with pain in the upper abdomen of 7 days duration, loose motion and occasional bilious vomiting. He had no significant past medical history. On general examination, there was gross pallor, temperature of 100-degree fahrenheit and a pulse rate of 107/minute. There was mild abdominal distension with a visible mass over the right hypochondrium. A tender mass of $4 \times 5 \text{ cm}^2$ was palpable over right hypochondrium with localized rigidity. Bowel sound was sluggish. His hemoglobin level was 4 gm/dL with a leukocyte count of $11 \times 10^9/\text{L}$. The retroviral status was negative. The clinical diagnosis was made as small bowel intussusceptions with the differential diagnosis of appendicular mass, intestinal tuberculosis with clumped bowel, there were no air fluid levels or air under the diaphragm on an erect abdominal X-ray. The US abdomen and CECT abdomen report favored bowel intussusceptions with minimal fluid in the pelvis (Figure 1).

1.2. Surgical Course. The patient underwent emergency laparotomy. There were purulent collections in the right paracolic gutter and pelvis. The proximal jejunum at 10 cm

was grossly thickened with perforation of 0.7 cm at the antimesenteric border. There were multiple large nodes in the mesentery of the thickened jejunum (Figure 2). Resection and end-to-end anastomosis was done. Cut section of jejunum had a *fish flesh* appearance (Figure 3).

1.2.1. Post-Operative Status. Post operatively the patient needed ventilator support with parental nutrition. The microscopic sections from the resected jejunum, and the lymph nodes showed the tumor cells arranged in diffuse sheets admixed with numerous macrophages giving a "starry sky" pattern (Figure 4). The histopathological diagnosis was Non-Hodgkin lymphoma of jejunum-likely to be Burkitt's type. The surgical margin was free from tumor. The tumor stained positive for LCA- and PAN-B cell. CD 10, CD 20, BCL-6 was positive and KI-67 found positive in more than 80% of the cells. The peripheral smear did not show any blast cells. The bone marrow aspiration revealed hyperplastic marrow. Serum LDH level was 1361.5 U/L. The final postoperative diagnosis was Burkitt's Lymphoma of jejunum, Ann Arbor Stage II AEX, IPI Score 3: High Intermediate Risk, Lugano Stage: II E Risk Stratification For Treatment: High Risk [1].

The patient was started chemotherapy from 7th postop day. As a high-risk patient he received 4 total cycles (2

FIGURE 1: CECT abdomen-bowel mass at the right lumbar intussusceptions.

FIGURE 2: On laparotomy thickened jejunum with a small perforation at antimesenteric border.

cycles of CODOX-M alternating with 2 cycles of IVAC). The chemotherapy scheduled was Inj cyclophosphamide 800 mg/m^2 IV on day 1, and 200 mg/m^2 IV on days 2–5. Inj Adriamycin 40 mg/m^2 IV on day 1, Vincristine 1.5 mg/m^2 IV on days 1 and 8 (cycle 1), as well as on days 1, 8, and 15 (cycle 3). Inj Methotrexate 1200 mg/m^2 IV over 1 hour on day 10 and then $240 \text{ mg/m}^2/\text{h}$ for the next 23 hours; leucovorin rescue begins 36 hours from the start of the methotrexate infusion. Intrathecal cytarabine 70 mg on days 1 and 3. Intrathecal methotrexate 12 mg on day 15. IVAC (cycles 2 and 4) Inj Ifosfamide 1500 mg/m^2 IV on days 1–5, with mesna. Inj Etoposide 60 mg/m^2 IV on days 1–5. Inj Ara C 2 g/m^2 IV every 12 hours on days 1–2. Inj GCF 300 Microgram sc daily 24 hours after completion of chemotherapy. Intrathecal methotrexate 12 mg on day 5.

Marked improvement was noticed after the initiation of chemotherapy. Abdominal distension decreased and the patient tolerated oral fluids. He had vincristine induced peripheral neuropathy involving right lower limb and paralytic ileus following second CODOX-M course which was managed conservatively with symptomatic treatment, component therapy with packed RBC and platelet support. He developed Grade 4 neutropenia with fever which was managed with broad-spectrum antibiotics and colony stimulating factors.

FIGURE 3: Cut-open jejunum; *fish flesh* appearance.

FIGURE 4: Microscopy-tumor cells arranged in diffuse sheets admixed with numerous macrophages giving a "starry sky" pattern (H&E, x100).

After completion of chemotherapy, abdomen was soft, serum LDH was normal and CECT abdomen showed no residual disease. Patient was advised follow up once in a 3 month for 2 years and then once in 6 month. Patient was last followed up in Dec 2013 and had no evidence of disease clinically or on investigations.

2. Discussion

Burkitt's lymphoma (BL) is a high-grade aggressive B cell Non Hodgkin's lymphoma. It is one of the fastest growing human malignancies, with a 100% replication rate and a doubling time of approximately 18–25 hours [2]. The rapidity of volumetric doubling of this neoplasm may lead to an acute abdominal presentation, which may mimic other less rare diseases.

Lymphoma constitutes 15%–20% of all small intestine neoplasms. The Ileum is the most common site (60%–65%) involving small intestine lymphoma followed by jejunum (20%–25%), duodenum (6%–8%) and other sites (8%–9%).

The clinical presentation of small intestinal lymphoma is nonspecific and the patient may have symptoms, such as colicky abdominal pain, nausea, vomiting, distension. Rarely patient may present with acute intestinal obstruction or gastrointestinal bleeding. The intestinal obstruction resulted from direct compression of the lumen by an expanding mass or by intussusceptions of the projecting intraluminal mass.

[3–5]. The case presented with all the features of intussusceptions in form of pain abdomen, and vague abdominal lump at right hypochondrium.

Abdominal sonogram/CECT may show thickening of a segment of bowel or a target/pseudo kidney sign representing intussusceptions [6]. To diagnose primary small intestinal tumors clinically is difficult and in the emergency setting, the diagnosis of lymphoma is usually made postoperatively.

The purulent fluid collection in the abdominal cavity is due to perforation of proximal obstructed bowel. Spontaneous intestinal perforation is an uncommon complication of BL, even though previously reported in children [7]. Possible explanations for spontaneous gastrointestinal perforation are tumor necrosis, immune suppression and protein malnutrition.

Preoperative diagnosis is difficult in Burkitt's lymphoma involving the small bowel; therefore, the role of surgery is limited to the management of complications like perforation or obstruction. In the present case laparotomy was carried out for intussusception with features of peritonitis [8, 9].

Aggressive early chemotherapy must be initiated even if resection of bowel and complete resection of the mass has been performed as there have been no reports of cure with the resection alone.

The histopathological types seen in intestinal lymphoma of children and adolescents include Burkitt's Lymphoma, Diffuse Large B Cell Lymphoma (DLBCL) and rarely Hodgkin's Lymphoma [1, 7], and hence immune histochemistry is mandatory to differentiate the type of lymphoma.

The typical immunophenotype of BL is sIg+, CD10+, CD19+, CD20+, CD22+ TdT–, Ki67+ (>95%), BCL2–, BCL6+, and simple karyotype with MYC rearrangement. Most cases (80%) of classical BL are characterized by t(8; 14) which results in the juxtaposition of MYC gene from chromosome 8 with the IgH region on chromosome 14. Other variants with MYC rearrangements [t(8; 22) or t(2; 8)] are less common [1]. In the presented case the tumor stained positive for LCA- and PAN-B cell. CD 10, CD 20, BCL-6 was positive and Ki-67 expression was found in more than 80% of the cells.

The recommended workup in a case of intestinal lymphoma includes complete physical examination with attention to node-bearing areas, including Waldeyer's ring, and to size of liver and spleen. The performance status, serum LDH, comprehensive metabolic panel, serum uric acid, chest/abdominal/pelvic CT with contrast, lumbar puncture, flow cytometry of cerebrospinal fluid, and bone marrow aspiration should be taken into account [1]. For the presented case the serum LDH was grossly elevated with hypercellular bone marrow and normal CSF analysis. There was no hepatosplenomegaly.

Risk stratification categories include Low Risk (normal LDH, completely resected abdominal lesion or single extra-abdominal mass <10 cm) and High Risk. High risk includes patients presenting with intestinal obstruction or perforation. High Risk patients are given CALGB 10002 regimen + rituximab or CODOX-M (original or modified) ± rituximab or Dose-adjusted EPOCH or HyperCVAD + rituximab [1, 7]. In a prospective study, low-intensity EPOCH-R-based treatment was highly effective in adults with sporadic

or immunodeficiency-associated Burkitt's lymphoma [10]. There was a trend in favor of superiority of rituximab-containing therapy in all efficacy end points, including 3-year Progress free survival PFS (74% versus 61%) and 3-year OS (77% versus 66%). In addition, fewer relapses were observed [11].

Dose modifications are required depending upon pre-chemo hematological and biochemical parameters. Dose-adjusted EPOCH can be given for high-risk patients not able to tolerate aggressive treatment. Taking the patient age, pre-op clinical parameters, postop status and economic status into consideration the patient was started on CODOX-M/IVAC regimen in alternate cycles for four courses.

BL is curable in a significant subset of patients when treated with dose-intensive, multiagent chemotherapy regimens that also incorporate CNS prophylaxis. About 60% to 90% of pediatric and young adult patients with BL achieve durable remission if treated appropriately. The 5 year survival estimate is 56% and durable remission may be possible in approximately 60% of patients with BL [1].

In general, patients with low-stage disease (i.e., single extra-abdominal/extrathoracic tumor or totally resected intra-abdominal tumor) have an excellent prognosis (a 5-year survival rate of approximately 90%). Patients with high-stage (stage III or stage IV) mature B-lineage non-Hodgkin lymphoma (NHL) (Burkitt or Burkitt-like lymphoma) and diffuse large B-cell lymphoma have an 80% to 90% long-term survival [1]. On 18 months follow up the patient had no clinical symptoms and no radiological relapse.

The Event free survival has been markedly improved with multi-agent intensive chemotherapy like CODX-M/IVAC. In the presented case after establishing the diagnosis on seventh postop day the chemotherapy was started with a marked improvement [1, 7].

3. Conclusion

Burkitt's lymphoma is an aggressive, rapidly progressive malignancy and may present as jejunal perforation. The successful outcome depends on early postop diagnosis and aggressive chemotherapy with supportive care.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

Author's Contribution

Samir Ranjan Nayak, Ganni Bhaskara Rao, Subramanya Sarma Yerraguntla, and Sisir Bodepudi are contributed equally to this work.

Acknowledgment

The authors express their gratitude to Dr. Dilip Kumar Soren, Assistant Professor, Department of Surgery; Dr. Manisha Mahapatra M.D.; Dr. S. P. V. Turlapati, Professor, Department

of Pathology; and Dr. Sporthi, Resident, Department of Medicine.

References

- [1] *National Comprehensive Cancer Network Clinical Practice Guideline Version 1*, Burkitt Lymphoma, 2014.
- [2] K. A. Blum, G. Lozanski, and J. C. Byrd, "Adult Burkitt leukemia and lymphoma," *Blood*, vol. 104, no. 10, pp. 3009–3020, 2004.
- [3] B. Li, Y.-K. Shi, X.-H. He et al., "Primary non-Hodgkin lymphomas in the small and large intestine: clinicopathological characteristics and management of 40 patients," *International Journal of Hematology*, vol. 87, no. 4, pp. 375–381, 2008.
- [4] F. T. Hoxha, S. I. Hashani, A. S. Krasniqi et al., "Intussusceptions as acute abdomen caused by Burkitt lymphoma: a case report," *Cases Journal*, vol. 2, no. 12, article 9322, 2009.
- [5] J. Rao, C. L. Kwang, L. Chan, L. C. Khoon, and T. C. Ming, "Advanced Burkitt's lymphoma presenting with jejunal perforation," *Annals of the Academy of Medicine Singapore*, vol. 37, no. 3, pp. 249–250, 2008.
- [6] D. M. Biko, S. A. Anupindi, A. Hernandez, L. Kersun, and R. Bellah, "Childhood Burkitt lymphoma: abdominal and pelvic imaging findings," *American Journal of Roentgenology*, vol. 192, no. 5, pp. 1304–1315, 2009.
- [7] S. R. Goldberg, K. Godder, and D. A. Lanning, "Successful treatment of a bowel perforation after chemotherapy for Burkitt lymphoma," *Journal of Pediatric Surgery*, vol. 42, no. 3, pp. e1–e3, 2007.
- [8] D. A. Finch, M. S. Wilson, and S. T. O'Dwyer, "Successful management of jejunal perforation in Burkitt's lymphoma: a case report," *Case Report Surgery*, vol. 2012, Article ID 230538, 3 pages, 2012.
- [9] D. B. Gahukamble and A. S. Khamage, "Limitations of surgery in intraabdominal Burkitt's lymphoma in children," *Journal of Pediatric Surgery*, vol. 30, no. 4, pp. 519–522, 1995.
- [10] K. Dunleavy, S. Pittaluga, M. Shovlin et al., "low intensity therapy in adults with Burkitt's lymphoma," *The New England Journal of Medicine*, vol. 369, no. 20, pp. 1915–1925, 2013.
- [11] J. A. Barnes, A. S. LaCasce, Y. Feng et al., "Evaluation of the addition of rituximab to CODOX-M/IVAC for Burkitt's lymphoma: a retrospective analysis," *Annals of Oncology*, vol. 22, no. 8, pp. 1859–1864, 2011.